Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy

Cancer Immunology, Immunotherapy

Volumn 62, Issue 12, 2013, Pages 1821-1830

  Al Taei, Saly ^a   Banner, Russell ^a   Powell, Ned ^b   Evans, Mererid ^a   Palaniappan, Nachi ^a   Tabi, Zsuzsanna ^a   Man, Stephen ^b  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

HPV; Immunosuppression; OPC; T cells

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; VIRUS DNA;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; LYMPHOCYTE COUNT; MALE; MEMORY T LYMPHOCYTE; OROPHARYNX CANCER; PRIORITY JOURNAL;

CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYELOID CELLS; ONCOGENE PROTEINS, VIRAL; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84890435662     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1488-5     Document Type: Article

References (49)

1. Marur S, D'Souza G, Westra WH, Forastiere AA (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11:781-789. doi: 10.1016/s1470-2045(10)70017-6
2. Anonymous (2012) Oral Cancer Incidence Statistics. In: cancerresearchuk.org. http://www.cancerresearchuk.org/cancer-info/cancerstats/ types/oral/incidence/uk-oral-cancer-incidence-statistics. Accessed 19 Aug 2013
3. Begum S, Cao D, Gillison M et al (2005) Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res 11:5694-5699. doi: 10.1158/1078-0432.ccr-05-0587
4. D'Souza G, Kreimer AR, Viscidi R et al (2007) Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356:1944-1956. doi: 10.1056/NEJMoa065497
5. Munger K, Baldwin A, Edwards KM et al (2004) Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78:11451-11460. doi: 10.1128/jvi.78.21.11451-11460.2004
6. Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35. doi: 10.1056/NEJMoa0912217
7. Fakhry C, Westra WH, Li S et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261-269
8. Spanos WC, Nowicki P, Lee DW et al (2009) Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg 135:1137-1146. doi: 10.1001/archoto. 2009.159
9. Brandwein-Gensler M, Teixeira MS, Lewis CM et al (2005) Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol 29:167-178
10. Heusinkveld M, Goedemans R, Briet RJ et al (2012) Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. Int J Cancer 131:E74-E85. doi: 10.1002/ijc.26497
11. Kong CS, Narasimhan B, Cao H et al (2009) The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 74:553-561. doi: 10.1016/j.ijrobp.2009.02.015
12. Kreimer AR, Clifford GM, Snijders PJ et al (2005) HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. Int J Cancer 115:329-332. doi: 10.1002/ijc.20872
13. Hoffmann TK, Arsov C, Schirlau K et al (2006) T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer 118:1984-1991
14. De Costa AM, Young MR (2011) Immunotherapy for head and neck cancer: advances and deficiencies. Anticancer Drugs 22:674-681. doi: 10.1097/CAD.0b013e328340fd18
15. Davidson HC, Leibowitz MS, Lopez-Albaitero A, Ferris RL (2009) Immunotherapy for head and neck cancer. Oral Oncol 45:747-751. doi: 10.1016/j.oraloncology.2009.02.009
16. Rapidis AD, Wolf GT (2009) Immunotherapy of head and neck cancer: current and future considerations. J Oncol 2009:346345. doi: 10.1155/2009/346345
17. Allen CT, Judd NP, Bui JD, Uppaluri R (2012) The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope 122:144-157. doi: 10.1002/lary.21913
18. Distel L, Buttner M (2012) Radiochemotherapy fosters a favorable pattern of inflammatory cells in head and neck tumors. Oncoimmunology 1:982-983. doi: 10.4161/onci.20200
19. Strauss L, Bergmann C, Gooding W et al (2007) The frequency and suppressor function of CD4+ CD25 highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13:6301-6311. doi: 10.1158/1078-0432.CCR-07-1403
20. Schaefer C, Kim GG, Albers A et al (2005) Characteristics of CD4+ CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 92:913-920. doi: 10.1038/sj.bjc.6602407
21. Strauss L, Bergmann C, Whiteside TL (2009) Human circulating CD4+ CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol 182:1469-1480
22. Mandapathil M, Szczepanski MJ, Szajnik M et al (2009) Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res 15:6348-6357. doi: 10.1158/1078-0432.ccr- 09-1143
23. Sevko A, Umansky V (2013) Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J Cancer 4:3-11. doi: 10.7150/jca.5047
24. Byers LA, Holsinger FC, Kies MS et al (2010) Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 9:1755-1763. doi: 10.1158/1535-7163.mct-09-1047
25. Brandau S, Trellakis S, Bruderek K et al (2011) Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol 89:311-317. doi: 10.1189/jlb.0310162
26. Serafini P, Meckel K, Kelso M et al (2006) Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203:2691-2702. doi: 10.1084/jem.20061104
27. Hoechst B, Ormandy LA, Ballmaier M et al (2008) A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 135:234-243. doi: 10.1053/j.gastro.2008.03.020
28. Vasievich EA, Huang L (2011) The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm 8:635-641. doi: 10.1021/mp1004228
29. Smith KL, Tristram A, Gallagher KM et al (2005) Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. Int Immunol 17:167-176. doi: 10.1093/intimm/dxh197
30. Welters MJ, de Jong A, van den Eeden SJ et al (2003) Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 63:636-641
31. Hibbitts S, Rieck GC, Hart K et al (2006) Human papillomavirus infection: an anonymous prevalence study in South Wales, UK. Br J Cancer 95:226-232. doi: 10.1038/sj.bjc.6603245
32. Jacobs MV, Snijders PJ, van den Brule AJ et al (1997) A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 35:791-795
33. Weng NP, Araki Y, Subedi K (2012) The molecular basis of the memory T cell response: differential gene expression and its epigenetic regulation. Nat Rev Immunol 12:306-315. doi: 10.1038/nri3173
34. Kenter GG, Welters MJP, Valentijn ARPM et al (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361:1838-1847. doi: 10.1056/NEJMoa0810097
35. Kuss I, Donnenberg AD, Gooding W, Whiteside TL (2003) Effector CD8+CD45RO-CD27-T cells have signalling defects in patients with squamous cell carcinoma of the head and neck. Br J Cancer 88:223-230. doi: 10.1038/sj.bjc.6600694
36. Albers AE, Schaefer C, Visus C et al (2009) Spontaneous apoptosis of tumor-specific tetramer +CD8+ T lymphocytes in the peripheral circulation of patients with head and neck cancer. Head Neck 31:773-781. doi: 10.1002/hed.21031
37. Hoffmann TK, Dworacki G, Tsukihiro T et al (2002) Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8:2553-2562
38. Badoual C, Hans S, Merillon N et al (2013) PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 73:128-138. doi: 10.1158/0008-5472.CAN-12-2606
39. Jung AC, Guihard S, Krugell S et al (2012) CD8-alpha T-cell infiltration in human papillomavirus-related oropharyngeal carcinoma correlates with improved patient prognosis. Int J Cancer 132:E26-E36. doi: 10.1002/ijc.27776
40. Ward M, Mellows T, Riley C et al (2013) OP027. Oral Oncol 49:S14. doi: 10.1016/j.oraloncology.2013.03.035
41. Wansom D, Light E, Worden F et al (2010) Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 136:1267-1273. doi: 10.1001/archoto.2010.211
42. Choo DK, Murali-Krishna K, Anita R, Ahmed R (2010) Homeostatic turnover of virus-specific memory CD8 T cells occurs stochastically and is independent of CD4 T cell help. J Immunol 185:3436-3444. doi: 10.4049/jimmunol.1001421
43. Gattinoni L, Finkelstein SE, Klebanoff CA et al (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202:907-912. doi: 10.1084/jem.20050732
44. Gelbard A, Garnett CT, Abrams SI et al (2006) Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res 12:1897-1905. doi: 10.1158/1078-0432.ccr-05- 1761
45. Suzuki Y, Mimura K, Yoshimoto Y et al (2012) Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 72:3967-3976. doi: 10.1158/0008-5472.can-12-0851
46. Duray A, Demoulin S, Hubert P et al (2010) Immune suppression in head and neck cancers: a review. Clin Dev Immunol 2010:701657. doi: 10.1155/2010/701657
47. Badoual C (2006) Prognostic value of tumor-infiltrating CD4 + T-Cell subpopulations in head and neck cancers. Clin Cancer Res 12:465-472. doi: 10.1158/1078-0432.CCR-05-1886
48. Lyford-Pike S, Peng S, Young GD et al (2013) Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 73:1733-1741. doi: 10.1158/0008-5472.CAN-12-2384
49. Corzo CA, Condamine T, Lu L et al (2010) HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 207:2439-2453. doi: 10.1084/jem.20100587